```html

Junctional Tachycardia (Atrioventricular Nodal Re‑entrant Tachycardia)

Overview

Junctional tachycardia, more precisely called atrioventricular nodal re‑entrant tachycardia (AVNRT), is a type of supraventricular tachycardia (SVT) that originates from a re‑entry circuit within the atrioventricular (AV) node. The abnormal circuit causes the heart to beat unusually fast—typically 150–250 beats per minute (bpm)—while the rhythm remains regular.

Who it affects: AVNRT is the most common SVT in both adults and children. It accounts for roughly 35–45 % of all SVT cases. The condition is slightly more prevalent in women (about 60 % of cases) and often presents in the second to fourth decades of life, although it can appear at any age, even in infants.

Prevalence: Epidemiologic data suggest that up to 2.5 % of the general population will experience at least one episode of AVNRT in their lifetime, with an incidence of 0.5–2 per 1,000 persons per year. The condition is usually benign, but recurrent episodes can impair quality of life and, rarely, lead to serious complications if left untreated.

Symptoms

Symptoms may be abrupt and can vary from mild to severe. The classic presentation is a sudden “fluttering” or “racing” heartbeat that starts and stops suddenly.

• Palpitations – rapid, regular thumping sensation in the chest.
• Chest discomfort – pressure, tightness, or mild pain, especially during an episode.
• Shortness of breath – difficulty catching breath, often worsened by activity.
• Dizziness or light‑headedness – may progress to presyncope.
• Syncope (fainting) – uncommon, usually indicates a very rapid rate or underlying heart disease.
• Fatigue – lingering tiredness after episodes due to temporary reduced cardiac output.
• Neck pulsations – visible “jogging” of the jugular vein (jugular venous pulsation).
• Feeling of anxiety or panic – the rapid heart rate can trigger a stress response.
• Cold sweats – profuse perspiration during an attack.

Most patients describe the onset as “instantaneous” and the termination as “just as sudden.” Episodes can last seconds to several hours, and some individuals may have multiple attacks per day.

Causes and Risk Factors

Pathophysiology

AVNRT involves two pathways within or adjacent to the AV node:

• Fast pathway – conducts impulses quickly but has a relatively long refractory period.
• Slow pathway – conducts more slowly but recovers faster.

A premature atrial beat can travel down the slow pathway while the fast pathway is still refractory. The impulse then circulates retrogradely up the fast pathway, creating a continuous loop of electrical activity—this is the “re‑entry” circuit that drives the rapid heart rate.

Risk Factors

• Female sex (≈60 % of cases).
• Age 20–40 years (peak incidence).
• Structural heart disease is *not* required, but concomitant conditions such as congenital heart defects, hypertension, or coronary artery disease can increase susceptibility.
• Familial predisposition – rare, but some families show clustering of AVNRT.
• Triggers: caffeine, alcohol, nicotine, recreational drugs (cocaine, amphetamines), certain over‑the‑counter decongestants, and intense emotional or physical stress.
• Electrolyte disturbances (especially low potassium or magnesium).

Diagnosis

Diagnosis rests on a combination of history, physical examination, and targeted cardiac testing.

Electrocardiogram (ECG)

• During an episode – a narrow‑complex (QRS < 120 ms) tachycardia at 150–250 bpm with a regular rhythm.
• Typical patterns:
  • Short RP interval (P‑wave appears after the QRS or is hidden within the QRS).
  • Absent or retrograde P‑waves (often seen as a “pseudo‑R’” in V1).

Event Recorders & Holter Monitors

If the episode is infrequent, a 24‑hour Holter or a wearable event recorder can capture the rhythm for later analysis.

Electrophysiology Study (EPS)

Invasive EPS is the gold‑standard when non‑invasive tests are inconclusive or when catheter ablation is being considered. It reproduces the re‑entry circuit with programmed stimulation and allows precise mapping of the slow pathway.

Other Tests (as needed)

• Transthoracic echocardiogram – to rule out structural heart disease.
• Blood tests – electrolytes, thyroid function, drug screen if indicated.

Treatment Options

Management is individualized based on symptom severity, frequency of episodes, and patient preference.

Acute Termination (During an Episode)

1. Vagal maneuvers – bearing down (Valsalva), carotid sinus massage (performed only by trained professionals), or ice water immersion. Successful in ~20–30 % of cases.
2. Pharmacologic therapy
   • Adenosine – 6 mg rapid IV push; if ineffective, repeat with 12 mg. Works within seconds and is safe in most patients without contraindications (e.g., second‑degree AV block, sick sinus syndrome).
   • Intravenous beta‑blockers (e.g., metoprolol) or calcium‑channel blockers (e.g., diltiazem) if adenosine is contraindicated.

Long‑Term Management

• Medication
  • Beta‑blockers (metoprolol, atenolol) – reduce AV nodal conduction.
  • Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem) – especially useful in patients with asthma or COPD where beta‑blockers are less desirable.
  • Anti‑arrhythmic agents (flecainide, propafenone) – reserved for refractory cases.
• Catheter Ablation – radiofrequency or cryoablation of the slow pathway. Success rates >95 % with <1 % risk of permanent AV block. Recommended for patients with:
  • Frequent or debilitating episodes.
  • Intolerance or contraindication to medications.
  • Pregnancy (often preferred over chronic drug therapy).
• Lifestyle Modification – avoidance of identified triggers (caffeine, alcohol, smoking), stress‑reduction techniques, and adequate sleep.

Living with Junctional Tachycardia (AVNRT)

While AVNRT is usually not life‑threatening, it can affect daily life. Below are practical tips:

• Know your triggers – keep a diary of episodes, noting food, drink, stressors, and medications.
• Learn vagal maneuvers – practice the Valsalva technique (10‑second forced exhalation against a closed airway) so you can use it quickly when an episode starts.
• Medication adherence – take prescribed drugs exactly as directed; never stop abruptly without consulting your doctor.
• Regular follow‑up – annual cardiac review, or sooner if symptoms change.
• Exercise safely – most patients can engage in moderate aerobic activity. Warm up gradually and avoid extreme exertion if you notice palpitations.
• Pregnancy considerations – discuss treatment options early; many women undergo successful catheter ablation before conception or use beta‑blockers during pregnancy.
• Emergency plan – carry a card with your diagnosis, emergency contacts, and medications (e.g., a dose of adenosine prescribed for self‑administration is rare but some centers provide auto‑injectors).

Prevention

Because AVNRT is often related to modifiable triggers, prevention focuses on lifestyle and medical optimization.

• Limit caffeine (<200 mg/day) and avoid energy drinks.
• Reduce or eliminate alcohol consumption, especially binge drinking.
• Quit smoking and avoid recreational stimulants.
• Maintain electrolyte balance – adequate potassium (≈3.5–5.0 mmol/L) and magnesium intake, especially after intense exercise or vomiting.
• Manage stress through mindfulness, yoga, or counseling.
• Control comorbidities: hypertension, sleep apnea, hyperthyroidism.
• Review over‑the‑counter decongestants or weight‑loss pills with a pharmacist; many contain sympathomimetic agents that can precipitate SVT.

Complications

Although AVNRT itself is generally benign, untreated or poorly controlled cases can lead to:

• Heart failure – chronic tachycardia may cause tachycardia‑induced cardiomyopathy.
• Syncope – due to reduced cerebral perfusion during a rapid episode.
• Ischemic chest pain – especially in patients with underlying coronary artery disease.
• Psychological impact – anxiety, panic disorder, or depression from recurrent episodes.
• Permanent AV block – rare, usually iatrogenic after ablation; may require pacemaker implantation.

Early recognition and appropriate therapy dramatically reduce these risks.

When to Seek Emergency Care

---

Sources: Mayo Clinic; American College of Cardiology (ACC) guidelines; European Society of Cardiology (ESC) 2023 SVT consensus; National Heart, Lung, and Blood Institute (NHLBI); Cleveland Clinic; peer‑reviewed articles in the Journal of the American College of Cardiology and Heart Rhythm. All URLs accessed July 2024.

```